These results demonstrate reduced DR5:GFP distribution and PIN1-immuno-density signal intensities at all the time points of HL treatment (Fig. 5a, b and Supplementary Fig. 9a). The gene discussed is TNFRSF10B; the disease is Hodgkins lymphoma.